Core Viewpoint - Teladoc Health has experienced a significant decline in stock value, currently trading about 98% lower than its peak in February 2021, raising questions about whether the shares are undervalued enough to consider a buy [1][2]. Financial Performance - In Q3 2025, Teladoc's revenue decreased by 2% year over year to approximately $626 million, with integrated care revenue rising by 2% to about $390 million, while BetterHelp revenue fell by 8% to around $237 million [4]. - The company reported a net loss of $49.5 million in Q3, which included a $12.6 million non-cash goodwill impairment charge, indicating ongoing struggles despite generating $67.9 million in free cash flow [11][12]. Membership and Growth Metrics - Teladoc's U.S. integrated care membership reached 102.5 million, reflecting a 9% year-over-year increase, while chronic care program enrollment was 1.17 million, showing a slight decline of 1% year over year but a sequential increase of over 4% [5]. - Key metrics for BetterHelp, such as conversion rates and user growth, are reportedly trending as expected, although the direct-to-consumer cash-pay business faces challenges due to competition [7][8]. Future Outlook - The company anticipates Q4 2025 revenue to be between $622 million and $652 million, which is lower than the previous year's Q4 revenue of approximately $640 million [13]. - Management has indicated that 2025 will be a "repositioning year" focused on product changes and improving the value proposition, particularly for BetterHelp [2][6].